The newly updated mRNA vaccines from Pfizer and Moderna, which target KP.2, the dominant strain last spring, and the Novovax vaccine, which targets JN.1, should be effective against XEC.

Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...

Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...

Moderna and Johnson & Johnson — were all either developed or tested using fetal cells that originated in abortion, and she ...

Moderna has received Health Canada's approval for its respiratory syncytial virus messenger ribonucleic acid (mRNA) vaccine ...

Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...

Recent health news highlights include Recordati's nonchalance towards potential U.S. tariffs, Canada's approval of Moderna's ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

Let's consider two examples: Vertex Pharmaceuticals (NASDAQ: VRTX) and Moderna (NASDAQ: MRNA). Here's why these biotechs are ...

Bank of America Securities analyst Alec Stranahan reiterated a Hold rating on Moderna (MRNA – Research Report) today and set a price ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Health professionals recommend vaccines before traveling to celebrate the holidays with family. If you missed the early fall ...